Mechanistically, we demonstrate that the effects of sorafenib in NSCLC cells are independent of the MAPK pathway and rely instead on early inhibition of MKNK (also known as MNK) activity and STAT3 phosphorylation, and later down-regulation of MCL1 and EGFR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.